CAS: 2438-72-4 - bufexamac
Formula:C12H17NO3
InChI:InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
InChI key:InChIKey=MXJWRABVEGLYDG-UHFFFAOYSA-N
SMILES:O=C(NO)CC1=CC=C(OCCCC)C=C1
- Synonyms:
- 2-(4-Butoxyphenyl)Acetohydroxamic Acid
- 2-(4-butoxyphenyl)-N-hydroxyacetamide
- 2-(p-Butoxyphenyl)acetohydroxamic acid
- 4-Butoxy-N-hydroxybenzeneacetamide
- 4-Butoxyphenylacethydroxamic acid
- Acetohydroxamic acid, 2-(p-butoxyphenyl)-
- Anderm
- Benzeneacetamide, 4-butoxy-N-hydroxy-
- Bufexamic acid
- Cp 1044J3
- See more synonyms
- Droxarol
- Droxaryl
- Feximac
- Flogocid
- Flogocid N plastigel
- Malipuran
- Mofenar
- Norfemac
- Parfenac
- Parfenal
- Trolab
- p-Butoxyphenylacethydroxamic acid
- p-Butoxyphenylacetohydroxamic acid
Bufexamac
CAS:2438-72-4
Formula:
C12H17NO3
Purity:
>98.0%(HPLC)
Color and Shape:
White to Almost white powder to crystal
Molecular weight:
223.27
- Functional Groups
- Anti-inflammatory
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Enzyme Activators and Inhibitors
- See more categories
- Enzymes
- Immunology and Inflammation
- Cyclooxygenase (COX) Inhibitors
- Active Pharmaceutical Ingredient (API) Related Compounds for Research
- Biochemicals and Reagents
- Cellular and Molecular Biology
Ref: 3B-B4179
5g | 71.00 € |
Estimated delivery in United States, on Thursday 25 Apr 2024
Bufexamac CRS
CAS:2438-72-4
Formula:
C12H17NO3
Color and Shape:
Crystalline Powder. White. Powder.
Molecular weight:
223.2683
Ref: 41-B1156000
100mg | 115.00 € |
Estimated delivery in United States, on Tuesday 30 Apr 2024
Bufexamac
CAS:2438-72-4
Bufexamac (Bufexamic acid) is a COX inhibitor for IFN-α release with anti-inflammatory, analgesic, and antipyretic …
Formula:
C12H17NO3
Purity:
98%
Color and Shape:
Acicular Crystal
Molecular weight:
223.27
Ref: TM-T0867
50mg | 42.00 € | |
100mg | 52.00 € | |
200mg | 68.00 € | |
500mg | 94.00 € | |
1ml*10 (DMSO) | 35.00 € |
Estimated delivery in United States, on Thursday 2 May 2024
Bufexamac
CAS:2438-72-4
Formula:
C12H17NO3
Purity:
98%
Color and Shape:
Solid
Molecular weight:
223.2683
- Functional Groups
- Anti-inflammatory
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Enzyme Activators and Inhibitors
- See more categories
- Active Pharmaceutical Ingredients (API) for research
- Enzymes
- Immunology and Inflammation
- Cyclooxygenase (COX) Inhibitors
- Other Inhibitors
- Active Pharmaceutical Ingredient (API) Related Compounds for Research
- Biochemicals and Reagents
- Cellular and Molecular Biology
Ref: AN-AG007NMA
1g | 31.00 € | |
5g | 56.00 € | |
25g | 131.00 € | |
100g | 228.00 € | |
500g | 670.00 € | |
250mg | 27.00 € |
Estimated delivery in United States, on Thursday 2 May 2024
Ref: 86-MM0179.00
500mg | 1,339.00 € |
Estimated delivery in United States, on Tuesday 7 May 2024
Ref: 04-C10830500
100mg | 60.00 € |
Estimated delivery in United States, on Tuesday 7 May 2024
Bufexamac
CAS:2438-72-4
Formula:
C12H17NO3
Purity:
≥ 97.0%
Color and Shape:
White to off-white powder or crystals
Molecular weight:
223.27
Ref: 7W-GP6678
5g | 80.00 € |
Estimated delivery in United States, on Thursday 9 May 2024
2-(4-Butoxyphenyl)-N-hydroxyacetamide
CAS:2438-72-4
Purity:
95.0%
Color and Shape:
Solid
Molecular weight:
223.27200317382812
Ref: 10-F318152
5g | To inquire | |
250mg | To inquire |
Estimated delivery in United States, on Tuesday 14 May 2024
Bufexamac
CAS:2438-72-4
Applications Bufexamac is a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10). Bufexamac …
Formula:
C12H17NO3
Color and Shape:
White
Molecular weight:
223.27
Ref: TR-B689390
5g | 259.00 € | |
50mg | 93.00 € | |
500mg | 176.00 € |
Estimated delivery in United States, on Wednesday 12 Jun 2024
Bufexamac
CAS:2438-72-4
Bufexamac is a non-steroidal antiinflammatory drug that belongs to the class of pyridyl-2-one derivatives. It …
Formula:
C12H17NO3
Purity:
Min. 95%
Molecular weight:
223.27 g/mol
Ref: 3D-CAA43872
1g | To inquire | |
5g | To inquire | |
10g | To inquire | |
250mg | To inquire | |
500mg | To inquire |
Estimated delivery in United States, on Thursday 13 Jun 2024